NAFDAC Removes 101 Substandard Drugs From Nigerian Market
Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) has taken decisive action to ensure the safety of pharmaceutical products in the country. The agency has withdrawn, suspended, or cancelled the Certificates of Registration of 101 products, affecting hundreds of items across various categories.
The affected products, from companies such as Sanofi Aventis Nigeria ltd, Novartis Nigeria Limited, Bayer East Africa Limited, Healthline Limited, and Fensyl MHP Consulting Ltd, include widely used drugs like Abacavir tablets, Amaryl tablets, and Amlodipine. The list, accessible on NAFDAC's website, covers a wide range of medicines, including antimalarials, cardiovascular drugs, insulin/growth-hormone injectables, diabetes medicines, inhalers, and eye drops.
NAFDAC's move is part of its ongoing effort to combat the global issue of substandard and falsified medical products, which pose significant health risks to millions of people worldwide. The agency recently sought the collaboration of pharmacists to tackle this problem, aligning with its mission to address growing global concerns over fake and substandard medicines. The affected products are no longer permitted for manufacture, importation, exportation, distribution, advertisement, sale, and use within Nigeria.
NAFDAC's decision to remove 101 pharmaceutical products from the market underscores its commitment to ensuring the safety and efficacy of drugs in Nigeria. While specific reasons for the removal of these products are not available in the given context, the action is a stern warning to pharmaceutical companies to adhere to the required standards. Consumers are advised to be vigilant and ensure they use only approved and certified pharmaceutical products.
Read also:
- Comprehensive Overview of Addressing Traumatic Brain Injuries (TBIs)
- Enhanced Health Services Provisioned by San Diego Academic Health Partnership Continues During COVID-19 and Beyond
- Vaccination drive targeting infants under 6 months old against bronchiolitis in the region of Andalucia
- Biopsy Basics: Objectives, Varieties, and Potential Hazards - Healthline Illuminated
